The global anticancer drugs market size is estimated to expand to US$157.6 BN by 2026 with a 6.7% CAGR within the forecast period of 2019 to 2026.
The report analyzes and forecasts the anticancer drugs market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of anticancer drugs, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major anticancer drugs companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of anticancer drugs upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of anticancer drugs and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global anticancer drugs market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the anticancer drugs market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of anticancer drugs market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
The report also profiles major players in the anticancer drugs market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, Eli Lilly and Company, CELGENE CORPORATION, Novartis AG, Pfizer Inc, Amgen Inc, Bayer AG, AstraZeneca, Takeda Pharmaceutical Company Limited, Merck & Co., Inc. etc.
The global anticancer drugs market has been segmented as follows:
Global Anticancer drugs Market, by Drug Type
Global Anticancer drugs Market, by Therapy Type
Global Anticancer drugs Market, by Cancer Type
Global Anticancer Drugs Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Anticancer Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Drug Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunity
4.3.4. Trends
4.4. Global Anticancer Drugs Market Analysis and Forecasts, 2017-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
4.7. Market Outlook
4.8. Pipeline Analysis
4.9. Disease Overview
4.10. Evolution of Cancer Therapies
5. Global Anticancer Drugs Market Analysis and Forecasts, By Drug Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Value Forecast By Drug Type , 2017-2026
5.3.1. Cytotoxic Drugs
5.3.1.1. Alkylating Agents
5.3.1.2. Antimetabolites
5.3.1.3. Others
5.3.2. Targeted Drugs
5.3.2.1. Monoclonal Antibodies
5.3.2.2. Tyrosine Kinase Inhibitors
5.3.2.3. Others
5.3.3. Hormonal Drugs
5.4. Market Attractiveness By Drug Type
6. Global Anticancer Drugs Market Analysis and Forecasts, By Therapy Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Therapy Type , 2017-2026
6.3.1. Chemotherapy
6.3.2. Targeted Therapy
6.3.3. Immunotherapy
6.3.4. Others
6.4. Market Attractiveness By Therapy Type
7. Global Anticancer Drugs Market Analysis and Forecasts, By Cancer Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Cancer Type , 2017-2026
7.3.1. Lung Cancer
7.3.2. Breast Cancer
7.3.3. Leukemia
7.3.4. Colorectal Cancer
7.3.5. Others
7.4. Market Attractiveness By Cancer Type
8. Global Anticancer Drugs Market Analysis and Forecasts, By Region
8.1. Key Findings
8.2. Market Value Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Region
9. North America Anticancer Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.2. Key Trends
9.2. Market Value Forecast By Drug Type , 2017-2026
9.2.1. Cytotoxic Drugs
9.2.1.1. Alkylating Agents
9.2.1.2. Antimetabolites
9.2.1.3. Others
9.2.2. Targeted Drugs
9.2.2.1. Monoclonal Antibodies
9.2.2.2. Tyrosine Kinase Inhibitors
9.2.2.3. Others
9.2.3. Hormonal Drugs
9.3. Market Value Forecast By Therapy Type , 2017-2026
9.3.1. Chemotherapy
9.3.2. Targeted Therapy
9.3.3. Immunotherapy
9.3.4. Others
9.4. Market Value Forecast By Cancer Type , 2017-2026
9.4.1. Lung Cancer
9.4.2. Breast Cancer
9.4.3. Leukemia
9.4.4. Colorectal Cancer
9.4.5. Others
9.5. Market Value Forecast By Country, 2017-2026
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Drug Type
9.6.2. By Therapy Type
9.6.3. By Cancer Type
9.6.4. By Country
10. Europe Anticancer Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.1.2. Key Trends
10.2. Market Value Forecast By Drug Type , 2017-2026
10.2.1. Cytotoxic Drugs
10.2.1.1. Alkylating Agents
10.2.1.2. Antimetabolites
10.2.1.3. Others
10.2.2. Targeted Drugs
10.2.2.1. Monoclonal Antibodies
10.2.2.2. Tyrosine Kinase Inhibitors
10.2.2.3. Others
10.2.3. Hormonal Drugs
10.3. Market Value Forecast By Therapy Type , 2017-2026
10.3.1. Chemotherapy
10.3.2. Targeted Therapy
10.3.3. Immunotherapy
10.3.4. Others
10.4. Market Value Forecast By Cancer Type , 2017-2026
10.4.1. Lung Cancer
10.4.2. Breast Cancer
10.4.3. Leukemia
10.4.4. Colorectal Cancer
10.4.5. Others
10.5. Market Value Forecast By Country / Sub-region, 2017-2026
10.5.1. U.K.
10.5.2. Germany
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Drug Type
10.6.2. By Therapy Type
10.6.3. By Cancer Type
10.6.4. By Country / Sub-region
11. Asia Pacific Anticancer Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.1.2. Key Trends
11.2. Market Value Forecast By Drug Type , 2017-2026
11.2.1. Cytotoxic Drugs
11.2.1.1. Alkylating Agents
11.2.1.2. Antimetabolites
11.2.1.3. Others
11.2.2. Targeted Drugs
11.2.2.1. Monoclonal Antibodies
11.2.2.2. Tyrosine Kinase Inhibitors
11.2.2.3. Others
11.2.3. Hormonal Drugs
11.3. Market Value Forecast By Therapy Type , 2017-2026
11.3.1. Chemotherapy
11.3.2. Targeted Therapy
11.3.3. Immunotherapy
11.3.4. Others
11.4. Market Value Forecast By Cancer Type , 2017-2026
11.4.1. Lung Cancer
11.4.2. Breast Cancer
11.4.3. Leukemia
11.4.4. Colorectal Cancer
11.4.5. Others
11.5. Market Value Forecast By Country / Sub-region, 2017-2026
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Drug Type
11.6.2. By Therapy Type
11.6.3. By Cancer Type
11.6.4. By Country / Sub-region
12. Latin America Anticancer Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.1.2. Key Trends
12.2. Market Value Forecast By Drug Type , 2017-2026
12.2.1. Cytotoxic Drugs
12.2.1.1. Alkylating Agents
12.2.1.2. Antimetabolites
12.2.1.3. Others
12.2.2. Targeted Drugs
12.2.2.1. Monoclonal Antibodies
12.2.2.2. Tyrosine Kinase Inhibitors
12.2.2.3. Others
12.2.3. Hormonal Drugs
12.3. Market Value Forecast By Therapy Type , 2017-2026
12.3.1. Chemotherapy
12.3.2. Targeted Therapy
12.3.3. Immunotherapy
12.3.4. Others
12.4. Market Value Forecast By Cancer Type , 2017-2026
12.4.1. Lung Cancer
12.4.2. Breast Cancer
12.4.3. Leukemia
12.4.4. Colorectal Cancer
12.4.5. Others
12.5. Market Value Forecast By Country / Sub-region, 2017-2026
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Drug Type
12.6.2. By Therapy Type
12.6.3. By Cancer Type
12.6.4. By Country / Sub-region
13. Middle East & Africa Anticancer Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.1.2. Key Trends
13.2. Market Value Forecast By Drug Type , 2017-2026
13.2.1. Cytotoxic Drugs
13.2.1.1. Alkylating Agents
13.2.1.2. Antimetabolites
13.2.1.3. Others
13.2.2. Targeted Drugs
13.2.2.1. Monoclonal Antibodies
13.2.2.2. Tyrosine Kinase Inhibitors
13.2.2.3. Others
13.2.3. Hormonal Drugs
13.3. Market Value Forecast By Therapy Type , 2017-2026
13.3.1. Chemotherapy
13.3.2. Targeted Therapy
13.3.3. Immunotherapy
13.3.4. Others
13.4. Market Value Forecast By Cancer Type , 2017-2026
13.4.1. Lung Cancer
13.4.2. Breast Cancer
13.4.3. Leukemia
13.4.4. Colorectal Cancer
13.4.5. Others
13.5. Market Value Forecast By Country / Sub-region, 2017-2026
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
13.6. Market Attractiveness Analysis
13.6.1. By Drug Type
13.6.2. By Therapy Type
13.6.3. By Cancer Type
13.6.4. By Country / Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis By Company (2016)
14.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.3.1. F. Hoffmann-La Roche Ltd
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Eli Lilly and Company
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Pfizer Inc
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Bayer AG
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. AstraZeneca
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.7. Takeda Pharmaceutical Company Limited
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Merck & Co., Inc.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. CELGENE CORPORATION
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview
14.3.10. Amgen Inc
14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.10.2. Product Portfolio
14.3.10.3. SWOT Analysis
14.3.10.4. Financial Overview
14.3.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers